Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepalatide in Chronic Hepatitis D
NCT06505928Phase 2Completed
- Sponsor
- Shanghai Hepu Pharmaceutical
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of hepalatide in hepatitis D (HDV), sponsored by Shanghai Hepu Pharmaceutical. Started Dec 2024; status: completed.
02
Drugs
hepalatide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT06505928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06505928.